5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Cohance Lifesciences Ltd.

•
cohance.comBSE: 543064NSE: COHANCE
Market Cap₹ 16,834 Cr.
Current Price
High / Low₹ 1,009 / 267
Stock P/E158.5
Book Value₹ 101
Price to Book2.97
Dividend Yield0.00 %
ROCE6.1 %
ROE4.0 %
Face Value₹ 1

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company is almost debt free
  • Promoters have been increasing their shareholding - up 7.4pp over 2 years
  • Company has consistently been profitable over the last 5 years
  • Company has delivered good sales growth of 17.6% CAGR over last 5 years
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.53x)

CONS

  • Recent results are weak - TTM profit is down 90.2% versus prior year
  • Valuation is stretched - P/E of 158.5 is well above its own 5-year median (60.6)
  • Company has delivered a poor profit growth of -16.2% over past five years
  • Operating margins have contracted to 18.8% from 46.3%
  • Recurring exceptional / one-off items are inflating headline profit

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.COHANCE440.00158.4716834.280.00-45.19-197.39422.26-23.136.120.27
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
3482312202534886046768405495565456194,223
1801321541803633984396114374354495204,774
Operating Profit1689966731252052372291121219599-551
OPM %48.27%42.69%30.06%29.00%25.63%34.01%35.10%27.27%20.39%21.77%17.51%15.94%-13.05%
11201417191622-46161-18122
Interest2122101011101099967
Depreciation131213173138445445444751495
Profit before Tax164105657110317420516163844120-429
Tax %26.44%24.52%28.59%24.67%26.85%20.62%24.97%27.18%26.07%20.75%28.52%58.26%-5.41%
Net Profit0000618208333874666298-452
4.743.121.842.101.983.634.023.161.281.940.960.51-0.63

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
3788341,0101,3201,3401,0512,6082,2692,142
2064495677397666461,8111,8421,882
Operating Profit172385443582574406797427260
OPM %45.40%46.15%43.87%44.06%42.84%38.60%30.56%18.82%12.13%
1181492466253511
Interest323129137413734
Depreciation112432394855167187192
Profit before Tax158405468668560406643207101
Tax %30.78%21.63%22.52%32.02%26.52%25.98%24.65%27.49%42.28%
Net Profit10931736245441130048415059
EPS0.0012.4514.2317.8316.1611.7919.144.68—
Dividend Payout %—20.08%14.05%28.05%37.14%0.00%0.00%0.00%—

COMPOUNDED SALES GROWTH

10 Years:
—
5 Years:
18%
3 Years:
19%

COMPOUNDED PROFIT GROWTH

10 Years:
—
5 Years:
-13%
3 Years:
-24%

STOCK PRICE CAGR

10 Years:
—
5 Years:
—
3 Years:
—
1 Year:
-56%

RETURN ON EQUITY

10 Years:
—
5 Years:
19%
3 Years:
12%
Last Year:
4%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2020

Sep 25

1:1

Employees Stock Option Plan & Bonus issue & Increase in Authorised Capital Inter alia, approved : 1. Issue of Bonus Shares The Board of Directors has considered, approved and recommended issue of (1:1) one Bonus Share for every one equity share held by the equity shareholders of the Company. The bonus issue of equity shares is subject to the approval of the shareholders in the ensuing annual general meeting and any other applicable statutory and regulatory approvals, as may be required. 2. The Second Annual General Meeting of the Company will be held on Monday the 14th day of September, 2020 at 11.30 a.m. IST. The Bonus shares once allotted shall rank pari-passu in all respects and carry the same rights of the existing Equity Shares and shall be entitled to participate in full in any dividend and other corporate action, recommended and declared, if any, after the issue and allotment of such Bonus Shares. 3. The Board of Directors has considered and approved increase in the Authorized Share Capital from Rs. 20.10 crores divided into 20.10 crores equity shares of Rs. 1/- each to Rs. 40.00 crores divided into 40.00 crores equity shares of Rs. 1/- each and consequential alteration in the Memorandum of Association of the Company, subject to the approval of shareholders of the Company. 4. The Board of Directors also approved granting of 10,00,000 (ten lakh only) Employee Stock options of Rs.1/- each under Suven Pharma Employee Stock Option Scheme 2020 (SPLESOP 2020) to the eligible employees of the Company and recommended to the members for their approval in the ensuing Annual General Meeting.

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital013252525252538
Minority Interest000000144123
5788321,1551,5021,7102,0233,5423,855
831861429670609501,026
Trade Payables5471831067042268285
102191171238235103550401
Total Liabilities8161,2921,5761,9672,1102,2545,4805,727
2713574415346636703,1073,369
Capital Work in Progress1111029630165179332173
7338542598536904337529
157175201283313231467562
00000134772681
Cash & Bank13141047685010260
25730728647436586362354
Total Assets8161,2921,5761,9672,1102,2545,4805,727

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
83493492514603385673368
Cash from Investing-65-413-311-136-195-362-390-255
Cash from Financing267-76-156-242-40-327-165
111-53720-18-44-51

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
50.1050.1050.1050.1066.4157.4957.4957.4957.49
9.8010.7010.8411.057.236.516.015.596.50
17.4216.9516.6716.6011.4020.8121.5721.7920.09
0.010.010.010.010.010.010.010.010.01
22.6722.2522.3722.2314.9515.1714.9215.1215.92

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-05
General Updates

2026-09-05 - Cohance Lifesciences Limited has informed the Exchange about Completion of USFDA Inspection

2026-09-03
Press Release

2026-09-03 - Cohance Lifesciences Limited has informed the Exchange regarding a press release dated September 03, 2026, titled "Press Release ".

2026-09-03
Committee Meeting Updates

2026-09-03 - Cohance Lifesciences Limited has informed the Exchange regarding Outcome of Committee Meeting held on September 03, 2026.

2026-08-27
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-27 - Cohance Lifesciences Limited has informed the Exchange about Schedule of meet

2026-08-27
Copy of Newspaper Publication

2026-08-27 - Cohance Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-26
General Updates

2026-08-26 - Cohance Lifesciences Limited has informed the Exchange about submission of BRSR

2026-08-26
General Updates

2026-08-26 - Cohance Lifesciences Limited has informed the Exchange about Integrated Annual Report 2026

2026-08-26
Shareholders meeting

2026-08-26 - Cohance Lifesciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on 17 September 2026

2026-08-13
Credit Rating- Others

2026-08-13 - Cohance Lifesciences Limited has informed the Exchange about Credit Rating- Others

News

Recent coverage and analyst commentary for COHANCE

Loading news…

🤖

AI Stock Analyst

Cohance Lifesciences Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme


5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login